Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?

by Alex Renner, Mauricio Burotto, Carlos Rojas
Published 2019-07-01

Breast Cancer Staging: Is TNM Ready to Evolve?

by Fernando Cadiz, Juan G. Gormaz, Mauricio Burotto
Published 2017-08-01

Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?

by Alex Renner, Suraj Rajesh Samtani, Arnaldo Marín, Mauricio Burotto
Published 2019-03-01

Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature

by Carlos Salinas, Alex Renner, Carlos Rojas, Suraj Samtani, Mauricio Burotto
Published 2020-06-01

Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.

by Mauricio Burotto, Julia Wilkerson, Wilfred Stein, Robert Motzer, Susan Bates, Tito Fojo
Published 2014-01-01

Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?

by Alex Renner, Mauricio Burotto, Jose Miguel Valdes, Juan Carlos Roman, Annerleim Walton-Diaz
Published 2021-07-01

MRI and Targeted Biopsy Essential Tools for an Accurate Diagnosis and Treatment Decision Making in Prostate Cancer

by Suraj Samtani, Mauricio Burotto, Juan Carlos Roman, Daniela Cortes-Herrera, Annerleim Walton-Diaz
Published 2021-08-01

Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors

by Samuel A. Kareff, MD, MPH, Suraj Samtani, MD, Mauricio Burotto, MD, MSc, Vinay Prasad, MD, MPH, Chul Kim, MD, MPH
Published 2021-04-01

Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.

by Krastan B Blagoev, Julia Wilkerson, Mauricio Burotto, Chul Kim, Edward Espinal-Domínguez, Pilar García-Alfonso, Meghna Alimchandani, Markku Miettinen, Montserrat Blanco-Codesido, Tito Fojo
Published 2017-01-01

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

by Howard Gurney, Thomas Powles, Laurence Albiges, Camillo Porta, Toni K Choueiri, Marc-Oliver Grimm, Elizabeth R Plimack, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Philippe Barthélémy, Christian K Kollmannsberger, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir, Mauricio Burotto, Daniel Castellano
Published 2020-12-01